XML 38 R29.htm IDEA: XBRL DOCUMENT

Subsequent Event	6 Months Ended
Subsequent Event	Jan. 31, 2023
Subsequent Events [Abstract]
Subsequent Event	Note 20. Subsequent Event On February 17, 2023, the Company acquired Isolere Bio, Inc. (Isolere), headquartered in Durham, North Carolina, U.S. for $62.5 million. Isolere delivers tailored manufacturing solutions designed to accelerate development to the clinical trial phase, reduce cost and challenges of scaling from clinical trials to commercial productions, and improve global access to life changing medicines and vaccines. Isolere will be reported within the Company’s Life Sciences segment. Management expects to finalize the purchase accounting by the second quarter of fiscal 2024.